Loading market dashboard
Jade Biosciences, Inc.
JBIOHealthcareNASDAQUS
Loading disclosure news
News and disclosures filtered by period, publisher, and event group.
Select a headline to open the full news page in the app.
SAN FRANCISCO and VANCOUVER, British Columbia, June 05, 2026 (GLOBE NEWSWIRE) -- Jade Biosciences, Inc. (“Jade” or the “Company”) (Nasdaq: JBIO), a clinical-stage biotechnology company focused on developing best-in-class therapies for autoimmune diseases, today announced that it has closed its previously announced public offering of 11,500,000 shares of its common stock, including 1,500,000 shares sold pursuant to the underwriters' full exercise of their option to purchase additional shares. The shares of common stock were sold to the public at a price of $15.00 per share. The gross proceeds to Jade from the offering, before deducting the underwriting discounts and commissions and other offering expenses, were $172.5 million. All of the shares of common stock sold in the public offering were sold by Jade.
SAN FRANCISCO and VANCOUVER, British Columbia, June 03, 2026 (GLOBE NEWSWIRE) -- Jade Biosciences, Inc. ("Jade" or the "Company") (Nasdaq: JBIO), a clinical-stage biotechnology company focused on developing best-in-class therapies for autoimmune diseases, today announced the pricing of a public offering of 10,000,000 shares of its common stock.
SAN FRANCISCO and VANCOUVER, British Columbia, June 03, 2026 (GLOBE NEWSWIRE) -- Jade Biosciences, Inc. (“Jade” or the “Company”) (Nasdaq: JBIO), a clinical-stage biotechnology company focused on developing best-in-class therapies for autoimmune diseases, today announced the pricing of a public offering of 10,000,000 shares of its common stock. The shares of common stock are being sold to the public at a price of $15.00 per share. The gross proceeds to Jade from the offering, before deducting the underwriting discounts and commissions and other offering expenses, are expected to be $150.0 million, excluding any exercise of the underwriters' option to purchase additional shares. The offering is expected to close on June 5, 2026, subject to the satisfaction of customary closing conditions. In addition, Jade has granted the underwriters a 30-day option to purchase up to an additional 1,500,000 shares of common stock at the public offering price, less underwriting discounts and commissions. All of the shares of common stock to be sold in the public offering are being sold by Jade.
SAN FRANCISCO and VANCOUVER, British Columbia, June 03, 2026 (GLOBE NEWSWIRE) -- Jade Biosciences, Inc. (“Jade” or the “Company”) (Nasdaq: JBIO), a clinical-stage biotechnology company focused on developing best-in-class therapies for autoimmune diseases, today announced that it intends to offer and sell, subject to market and other conditions, shares of its common stock or, in lieu of common stock to certain investors that so choose, pre-funded warrants to purchase shares of its common stock, in a proposed underwritten public offering. All of the shares of common stock and pre-funded warrants to be sold in the proposed offering are being offered by Jade. In addition, Jade intends to grant the underwriters a 30-day option to purchase up to an additional 15% of the securities offered in the public offering, at the public offering price, less underwriting discounts and commissions. There can be no assurance as to whether or when the proposed public offering may be completed, or as to the actual size or terms of the proposed offering.
Jade Biosciences NASDAQ: JBIO said interim results from a Phase 1 healthy volunteer study of JADE101 showed rapid and durable reductions in serum IgA, supporting the company's plan to advance the antibody into patient studies for IgA nephropathy.
Jade Biosciences, Inc. (JBIO) Discusses Positive Interim Results From JADE101 Phase I Healthy Volunteer Study and Development Plans Transcript
Jade Biosciences, Inc. (NASDAQ:JBIO) reported interim Phase 1 results for JADE101 in immunoglobulin A nephropathy (IgAN), showing substantial and sustained reductions in immunoglobulin A (IgA), a favorable safety profile, and pharmacokinetic data that could support a convenient dosing schedule.
SAN FRANCISCO and VANCOUVER, British Columbia, June 01, 2026 (GLOBE NEWSWIRE) -- Jade Biosciences, Inc. (the “Company” or “Jade”) (Nasdaq: JBIO), a clinical-stage biotechnology company focused on developing best-in-class therapies for autoimmune diseases, today announced positive interim results from its Phase 1 trial evaluating JADE101, a novel, investigational anti-A Proliferation-Inducing Ligand (APRIL) monoclonal antibody in development for the treatment of immunoglobulin A nephropathy (IgAN). JADE101 is designed with ultra-high binding affinity to selectively block APRIL, a key driver of pathogenic IgA production in IgAN, a chronic autoimmune disease that frequently affects young adults and can lead to end-stage kidney disease over a patient's lifetime. These results will be presented in a focused oral session during the 63rd European Renal Association (ERA) Congress, taking place in Glasgow, Scotland, from June 3-6, 2026.
SAN FRANCISCO and VANCOUVER, British Columbia, May 29, 2026 (GLOBE NEWSWIRE) -- Jade Biosciences, Inc. (the “Company” or “Jade”) (Nasdaq: JBIO), a clinical-stage biotechnology company focused on developing best-in-class therapies for autoimmune diseases, today announced that it will host a conference call and webcast on Monday, June 1, 2026, at 8:00 a.m. ET to discuss results from the ongoing Phase 1 healthy volunteer study of JADE101. The data are expected to define the dosing strategy and further characterize JADE101's clinical profile as a potentially differentiated, disease-modifying anti–A Proliferation-Inducing Ligand (APRIL) monoclonal antibody for the treatment of immunoglobulin A nephropathy (IgAN).
SAN FRANCISCO and VANCOUVER, British Columbia, May 26, 2026 (GLOBE NEWSWIRE) -- Jade Biosciences, Inc. (“the Company” or “Jade”), (Nasdaq: JBIO), a clinical-stage biotechnology company focused on developing best-in-class therapies for autoimmune diseases, today announced the first participant has been dosed in a first-in-human (FIH) Phase 1 clinical trial of JADE201. JADE201 is an investigational, half-life extended, afucosylated monoclonal antibody targeting the B cell activating factor receptor (BAFF-R) designed to deplete B cells through a dual mechanism of action: enhanced antibody effector function and BAFF signal blockade. The Company expects interim FIH data in 2027.
Interim Phase 1 data in rheumatoid arthritis expected in 2027 are anticipated to inform indication prioritization across multiple potential autoimmune indications supported by BAFF-R biology JADE201 preclinical data demonstrated dose-dependent BAFF-R occupancy, an extended half-life, and sustained B cell depletion in non-human primates SAN FRANCISCO and VANCOUVER, British Columbia, May 26, 2026 (GLOBE NEWSWIRE) -- Jade Biosciences, Inc.
SAN FRANCISCO and VANCOUVER, British Columbia, May 26, 2026 (GLOBE NEWSWIRE) -- Jade Biosciences, Inc. (the “Company” or “Jade”) (Nasdaq: JBIO), a clinical-stage biotechnology company focused on developing best-in-class therapies for autoimmune diseases, today announced that the first participant has been dosed in JUNIPER, the Company's Phase 2 trial evaluating JADE101 in participants with immunoglobulin A nephropathy (IgAN). JADE101 is designed with ultra-high binding affinity to selectively block APRIL, a key driver of pathogenic IgA production in IgAN, a chronic autoimmune disease that frequently affects young adults and can lead to end-stage kidney disease over a patient's lifetime. Interim data from JUNIPER are expected in 2027.
SAN FRANCISCO and VANCOUVER, British Columbia, May 07, 2026 (GLOBE NEWSWIRE) -- Jade Biosciences, Inc. (“Jade” or the “Company”) (Nasdaq: JBIO), a biotechnology company focused on developing best-in-class therapies for autoimmune diseases, today announced financial results for the first quarter ending March 31, 2026, and provided a corporate update.
SAN FRANCISCO and VANCOUVER, British Columbia, April 23, 2026 (GLOBE NEWSWIRE) -- Jade Biosciences, Inc. (“Jade” or the “Company”) (Nasdaq: JBIO), a clinical-stage biotechnology company focused on developing best-in-class therapies for autoimmune diseases, today announced that Jade's Board of Directors granted an equity award to Edward R. Conner, M.D.
SAN FRANCISCO and VANCOUVER, British Columbia, April 22, 2026 (GLOBE NEWSWIRE) -- Jade Biosciences, Inc. (“Jade” or the “Company”) (Nasdaq: JBIO), a clinical-stage biotechnology company focused on developing best-in-class therapies for autoimmune diseases, today announced the appointment of Edward R. Conner, M.D.
